ArticlePreventing chronic disease2020
Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV.
Article in Preventing chronic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Ageing with HIV: Medicine Optimisation Challenges and Support Needs for Older People Living with HIV: A Systematic Review.Drugs & aging · 2023Pooled it
- What is polypharmacy in people living with HIV/AIDS? A systematic review.AIDS research and therapy · 2022Pooled it
- A systematic review of engagement in care and health care utilization among older adults living with HIV and non-communicable diseases.AIDS care · 2022Pooled it
- Investigating impact of theory of planned behavior-based educational intervention on HIV screening among healthcare staff.BMC health services research · 2025Trial
- Patient-Reported Outcomes After Switching to a 2-Drug Regimen of Fixed-Dose Combination Dolutegravir/Lamivudine: 48-Week Results from the SALSA Study.AIDS and behavior · 2025Trial
- Efavirenz and CYP2C9 Genetic Polymorphisms Reduce CYP2C9 Activity in Healthy Participants.Clinical and translational science · 2026Article
- Polypharmacy in HIV: Rethinking what counts and why it matters.HIV medicine · 2026Review
- Antiretroviral therapy use, self-reported adherence, and viral suppression among women living with HIV in Canada.HIV medicine · 2025Article
- Factors influencing antiretroviral therapy switching in people with virologically suppressed HIV-1: a cross-sectional multicenter study in France.AIDS (London, England) · 2025Observational
- Factors Associated with Adequate Quality of Life Levels in HIV Patients During a Five-Year Longitudinal Study.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2025Observational
- Determining the Feasibility of a Mail-In Saliva Sample Protocol for Persons Living with HIV in Two Urban Northeast United States Clinics.HIV/AIDS (Auckland, N.Z.) · 2025Article
- Antiretroviral therapy and associated drug interactions with cardiovascular drugs: a critical review.Frontiers in pharmacology · 2025Review
- An update on drug-drug interactions in older adults living with human immunodeficiency virus (HIV).Expert review of clinical pharmacology · 2024Review
- Outcomes of Bariatric Surgery in People With Human Immunodeficiency Virus: A Retrospective Analysis From the ATHENA Cohort.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Article
- Prevalence of polypharmacy and medication-related quality of life among adult patients in Al-Ahsa, Saudi Arabia.Journal of medicine and life · 2023Article
- Pharmacotherapeutic profile, polypharmacy and its associated factors in a cohort of people living with HIV in Brazil.AIDS research and therapy · 2023Article
- Barriers and facilitators to retention in care and treatment adherence among racially/ethnically diverse women with HIV in South Florida: a qualitative study.Women & health · 2023Article
- Dual trajectories of antiretroviral therapy adherence and polypharmacy in women with HIV in the United States.AIDS research and therapy · 2023Article
- The Influence of Anticipated HIV Stigma on Health-related Behaviors, Self-rated Health, and Treatment Preferences Among People Living with HIV in East Asia.AIDS and behavior · 2023Article
- Polypharmacy and health related quality of life among older adults on antiretroviral therapy in a tertiary hospital in Tanzania: a hospital-based cross-sectional study.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPeople living with HIV (PLHIV) have greater risk of having multiple health conditions. We measured the relationship between increased medication and overall quality of life among PLHIV from 24 countries.
methodsWe analyzed data for 2,112 adult PLHIV on antiretroviral therapy (ART) in 24 countries who completed the 2019 Positive Perspectives survey. Polypharmacy was defined as taking 5 or more pills a day or currently taking medications for 5 or more conditions. Outcomes were self-rated overall health, treatment satisfaction, and self-reported virologic control. New treatment concerns were issues not prioritized at ART initiation but now deemed paramount. Data were analyzed with descriptive and multivariable statistics.
resultsOverall prevalence of polypharmacy was 42.1%. People reporting polypharmacy had significantly poorer health outcomes independent of existing comorbidities; their odds of treatment satisfaction, optimal overall health, and virologic control were lower by 27.0% (adjusted odds ratio [AOR] = 0.73; 95% CI, 0.59-0.91), 36.0% (AOR = 0.64; 95% CI, 0.53-0.78), and 46.0% (AOR = 0.54, 95% CI, 0.42-0.70), respectively, compared with those without polypharmacy (all P < .05). Most PLHIV (56.6%) were concerned about taking more medicines as they age, and 73.1% were interested in ARTs with fewer medicines. Top reasons for switching ART among those who had ever switched (n = 1,550) were to reduce severity and frequency of side effects (45.3%), number of pills (35.0%), or number of medicines (26.8%). People reporting polypharmacy had significantly higher odds of having new concerns relative to when they initiated ART, regarding risks of drug-drug interactions (AOR = 1.32; 95% CI, 1.02-1.71) and side effects (AOR = 1.31; 95% CI, 1.02-1.68).
conclusionPolypharmacy was associated with poorer health-related outcomes among PLHIV. Many PLHIV expressed concerns about side effects of ART. Clinicians should carefully consider patient preferences, comorbidities, and drug profiles when prescribing ART.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.